Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies

Leukemia 2026

View at publisher

Authors: Yun Wang, Chunhua Li, Robert Peter Gale, Qi Liang, Neil E. Kay, Qianqian Huang, Yiling Song, Weida Wang, Y I X I U Liang

DOI: 10.1038/s41375-026-02970-x

Cited by: 3

References: 77

Fields of Study & Subjects

Chronic Lymphocytic Leukemia Research Statistical Methods in Clinical Trials Multiple Myeloma Research and Treatments

References 77